share_log

Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

puma biotechnology啓動ALISCA-Breast1 II期臨床試驗,以阿利瑟替治療雌激素受體陽性、HER2陰性轉移性乳腺癌
Benzinga ·  11/20 08:58

Puma Biotechnology Initiates ALISCA-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

puma biotechnology啓動ALISCA-Breast1 II期臨床試驗,針對激素受體陽性、HER2陰性的轉移性乳腺癌使用Alisertib。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論